Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12452858 | 0.86 | DAGLA (0.34) | DAGLAHDAC1HDAC8HDAC6 | |
| SCHEMBL13954062 | 0.85 | DAGLA (0.34) | DAGLAERAP2LNPEPTLR8HDAC1 | |
| SCHEMBL10025447 | 0.84 | DAGLA (0.34) | DAGLAHDAC1HDAC8HDAC6 | |
| SCHEMBL805233 | 0.83 | MAOA (0.36) | — | |
| SCHEMBL800475 | 0.82 | C3AR1 (0.38) | — | |
| SCHEMBL800465 | 0.80 | C3AR1 (0.37) | — | |
| SCHEMBL800486 | 0.79 | HDAC1 (0.34) | DAGLAHDAC1HDAC8HDAC6 | |
| SCHEMBL6197931 | 0.78 | HDAC1 (0.33) | DAGLAHDAC1HDAC8HDAC6 | |
| SCHEMBL10045826 | 0.77 | C3AR1 (0.39) | — | |
| SCHEMBL800815 | 0.77 | CTSL (0.44) | HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518928-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, TOP1 | DAGLA 4609/4885ERAP2 4234/4885LNPEP 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.